California regulators will delay the start of their hotly anticipated cap-and-trade rulemaking to early 2025, the agency confirmed to POLITICO on Thursday, November 14. The California Air Resources ...

The Biden administration has navigated a sometimes uneasy balance of seeding clean energy projects while limiting the growth of fossil fuel production on federal land and waters. But the Inflation ...

Democrats and Republicans are hoping to use the battle over the next farm bill, which has been stalled in Congress for nearly a year, as a way to message to rural voters. A critical vote is coming up ...

The urgency of disaster response needs could take up Congress’ immediate attention when lawmakers return after the election. While lawmakers involved in the permitting bill are optimistic about its ...

The conversation around representation in government has gained momentum, but has the demographic makeup of our leaders, legislators, and judges changed? We pulled together data on the race, sex, ...

Stay ahead of the personnel and policy changes across the federal landscape, including in the West Wing, in the Cabinet, federal agencies and Congress with POLITICO Pro. Gain advance access to ...

Lawmakers failed to resolve several key defense spending and policy battles ahead of the November elections, leaving unresolved issues that will dominate the upcoming lame-duck session. Chief among ...

Both chambers plan to take off most of August for recess and all of October ahead of elections. The House typically convenes for four-day weeks, while the Senate convenes up to five days a week.

Donald Trump’s first presidency inflicted serious damage on the European Union’s free-trade agenda. With the Republican challenger threatening to get even tougher if he wins a second term as U.S.

HHS’ first chief competition officer is headed to Capitol Hill to serve as chief health adviser on the Senate Finance Committee Democratic majority staff next month. Stacy Sanders will join the ...

The Biden administration will limit the cost of dozens of medicines for certain Medicare beneficiaries, using a new provision restricting drugmakers’ ability to hike prices beyond the inflation rate.